Androgen withdrawal induces the regression of human prostate cancers, but such cancers eventually become androgen-independent and metastasize. Thus, deciphering the mechanism of androgen withdrawalinduced apoptosis is critical to designing new therapies for prostate cancer. Previously, we showed that in the rat, castration-induced apoptosis is accompanied by a reduction in the expression of the apical caspase inhibitor FLICE-like inhibitory protein (FLIP). To test the functional role of FLIP in inhibiting prostate epithelial cell apoptosis, we employed the rat prostate epithelial cell line NRP-152, which differentiates to a secretory phenotype in a low-mitogen medium and then undergoes apoptosis following the addition of transforming growth factor B1 (TGFB1), mimicking androgen withdrawal -induced apoptosis. FLIP levels decline with TGFB1 treatment, suggesting that apoptosis is mediated by caspase-8 and indeed the caspase inhibitor crmA blocks TGFB1-induced apoptosis. Small interfering RNA -mediated knockdown of FLIP recapitulates and enhances TGFB1-induced cell death. NRP-152 cells stably transfected with constitutively expressed FLIP were refractory to TGFB1-induced apoptosis. TGFB1-induced caspase-3 activity is proportional to the level of cell death and inversely proportional to the level of FLIP expression in various clones. Moreover, neither caspase-3 nor PARP is cleaved in clones expressing high levels of FLIP. Furthermore, insulin, which inhibits differentiation, increases FLIP and inhibits TGFB-induced death in a FLIP-dependent manner. Although neither Fas-Fc, sTNFRII-Fc, nor DR5-Fc blocked TGFB1-induced cell death, there is a significant increase in tumor necrosis factor mRNA following TGFB stimulation, suggesting both an unexpected role for tumor necrosis factor in this model system and the possibility that FLIP blocks another unknown caspase-dependent mediator of apoptosis. (Mol Cancer Res 2008;6(2):231 -42) 
Introduction
Androgens regulate the growth of both normal and neoplastic prostate, and androgen signaling blockade is the primary treatment for late stage prostate cancer. Thus, there is an urgent need to understand the molecular events regulating androgen withdrawal -induced apoptosis (AWIA). As in humans, androgens promote mitosis and differentiation of rodent prostate ductal epithelium, and furthermore, seem to inhibit the apoptosis of differentiated cells (1) . After androgen ablation in rodents, the balance between mitosis and apoptosis is disrupted, and within 2 days, markers of apoptosis, such as fragmentation of chromosomal DNA, are evident (2, 3) . This wave of cell death results in the involution of the prostate gland (4) .
A variety of evidence supports the view that transforming growth factor h1 (TGFh1) is a paracrine and/or autocrine mediator of AWIA in the intact animal. AWIA is accompanied by an increase in TGFh1 mRNA, and the kinetics of mRNA induction closely parallel those of AWIA (5) . Additionally, there is a concomitant increase in the expression of the RI and RII subunits of the TGFh1 receptor (6) , as well as phosphorylated Smad2, a key downstream mediator of TGFh1 (4) . A dominant negative form of TGFh-RII blocks TGFh1-induced differentiation and cell death (7, 8) . Finally, administration of TGFh1 to rats results in the apoptosis of the prostate (5, 9) . Although the mechanism of TGFh1 action is unclear (it might involve transcriptional effects on proapoptotic and antiapoptotic proteins; ref. 10) , one potential downstream target is the family of death receptor (DR) signaling ligands.
Four extracellular ligands of the tumor necrosis factor (TNF) family initiate apoptosis through the DRs: TNFa, TNF-related apoptosis-inducing ligand (TRAIL), TWEAK, and FasL. The best characterized of these DR ligands is FasL, which signals through the Fas receptor to initiate a cascade of proximal and then distal caspase activation, release of the mitochondrial contents and further caspase activation. This leads to fragmentation of chromosomal DNA, various proteins, and cellular membranes, resulting in cell death (11, 12) . We have previously shown that one inhibitor of the DR pathways, FLICE-like inhibitory protein (FLIP), is down-regulated in the rat prostate following castration (2) . FLIP is overexpressed in human prostate cancers (13) , and loss of expression is associated with AWIA in vitro (14) and in vivo (2) . FLIP is an inactive homologue of caspase-8, an apical caspase activated in DR signaling. Like caspase-8, FLIP can be recruited to DRs following ligand binding via the adaptor molecule FADD. Elevated levels of FLIP can displace caspase-8 from the activated DR complex, acting as a dominant inhibitor of caspase-8 and thereby preventing the activation of distal caspases and cell death (15) . Surgical specimens from normal human prostate, as well as both androgen responsive and unresponsive tumors, express Fas and FasL (16, 17) . TRAIL induces the apoptosis of both normal prostate epithelial cells (18) and prostate cancer cell lines (19, 20) . TRAIL-induced apoptosis can be inhibited by FLIP (21, 22) . Many cancers are resistant to TRAIL-induced apoptosis due to the overexpression of FLIP. This resistance can be reversed by blocking FLIP expression using chemotherapeutics (23) or small interfering RNA (siRNA; refs. [24] [25] [26] [27] . Similarly, TNFa can induce the apoptosis of prostate cancer cell lines (28) and tumors in vivo (29) and also synergizes with chemotherapeutics which may alter FLIP levels (30) .
To test the functional role of FLIP in inhibiting prostate epithelial cell apoptosis, we employed the immortalized, nontumorigenic rat prostate epithelial cell line NRP-152 (NRP; ref. 31). When grown in mitogen-rich medium, these cells resemble prostate basal epithelia and divide rapidly. In mitogen-poor medium, growth is suppressed as the cells differentiate into a secretory phenotype (32) . The ability of NRP cells to replicate as basal-like epithelial cells and subsequently differentiate into secretory-like epithelial cells in vivo and in vitro suggests that this cell line is an excellent model for normal prostatic epithelium. It is the secretory epithelium of the prostate which apoptoses after androgen withdrawal. Importantly, the physiologic process of AWIA could be mimicked in NRP cells in vitro by the addition of TGFh1 to cultures previously differentiated in mitogen-poor medium. NRP cells maintained in mitogen-rich medium are resistant to TGFh1-induced apoptosis (33) . This is due, at least in part, to the activation of the Akt/mTOR pathway, which suppresses Smad3 activation (34) . Our previous observation that castration-induced down-regulation of FLIP in the rat prostate immediately precedes the onset of apoptosis, suggested that FLIP might have a functional role in regulating the apoptosis of prostate epithelium that occurs following androgen withdrawal. The current report tests this possibility, employing TGFh1-induced apoptosis of NRP cells as a model for AWIA in the rat prostate.
Results

TGFb1 Induces Apoptosis and Regulates FLIP in NRP Cells
NRP cells grown in rich medium (GM2), then replated in low growth factor medium (GM3), rapidly differentiate to a luminal (secretory) epithelial phenotype, both morphologically and biochemically (32) . The proliferation of these cells slows markedly from a doubling time of less than a day to >3 days ( Fig. 1A , gray columns; data not shown) but they do not apoptose (Fig. 1A, squares) . If, after 3 h in differentiation medium, the cells are treated with 5 ng of TGFh1/mL, the adherent live cells decline by about half at 2 days, whereas the apoptotic cells increase 10-fold relative to the untreated controls (Fig. 1A, black columns, circles) . Nucleosomal cleavage of DNA isolated after TGFh1 treatment shows that the apoptosis is evident as early as 10 h after the addition of TGFh1 (Fig. 1B) . Within 6 h, the activity of caspase-3 in TGFh1-treated cells is elevated relative to untreated NRP cells. Caspase-3 activity continues to increase through 36 h of TGFh1 treatment (Fig. 1C) . Because we have previously found that FLIP is reduced during rat prostate apoptosis, cytoplasmic protein isolated from the combination of adherent and floating cells at each time point was examined by immunoblotting for FLIP. FLIP is expressed in two major isoforms: FLIP long (FLIP L ), which has two DED domains at the NH 2 terminus followed by a caspase-8 -like domain containing inactivating mutations, and FLIP short (FLIP S ), which contains only the two DED domains. Both FLIP L and FLIP S can be detected by our DED-directed anti-FLIP antibody ( Supplementary Fig. S1 ), but only the long form is found in extracts of NRP cells ( Supplementary Fig. S1C ). FLIP protein is low when the NRP cells are replated in differentiation medium (time 0) and subsequently increases 24 to 72 h after differentiation ( Fig. 2A) . Differentiating NRP cells treated with TGFh1, in contrast, express low FLIP levels for up to 72 h following treatment, and the ratio of FLIP levels in treated versus untreated cells declines dramatically at all times examined ( Fig. 2A, graph) . TGFh1 treatment similarly reduces relative FLIP mRNA levels through 72 h when assessed by quantitative reverse transcription-PCR (Fig. 2B ).
TGFb1-Induced Apoptosis Is FLIP-and CaspaseDependent
The decline in FLIP levels in response to TGFh1 may leave NRP cells more vulnerable to apoptosis-induced preexisting death signals. To test this hypothesis, we used siRNA to reduce the endogenous level of FLIP L in NRP cells. We screened eight siRNAs for effective reduction in FLIP protein, and found two which led to 50% to 70% knockdown individually, but when combined, resulted in an 80% or more reduction in FLIP protein after 3 days (Fig. 3A, middle and bottom) . Reduction of FLIP L levels alone results in the death of differentiated NRP cells after 72 h (Fig. 3A , top, black columns), suggesting that there is a preexisting cell death signal in these cells. Treating these ''knocked down'' cells with TGFh1 resulted in additional cell death (Fig. 3A , top, gray columns), suggesting that TGFh1 induces cell death signals above the preexisting levels, in addition to reducing the endogenous death inhibition due to FLIP protection.
To further test the importance of FLIP in TGFh1-induced cell death, and because FLIP L is the endogenously expressed isoform in NRP cells ( Supplementary Fig. S1C ), we transiently transfected NRP cells with either FLIP L or the viral apical caspase inhibitor crmA. Although only f20% of transfected cells expressed the transgene when assessed by GFP cotransfection (data not shown), both FLIP L and crmA showed a trend (P < 0.1) toward protecting NRP cells from TGFh1-induced cell death, relative to the vector-only control (35% live versus 25% live cells relative to untreated transfectants; Fig. 3B ). NRP cell clones expressing crmA were isolated. CrmA expression protected NRP cells against TGFh1-induced apoptosis, with apoptosis rates ranging from 75% to 185% (relative to the untreated, differentiated control; see Materials and Methods), depending on the level of crmA expression (Fig. 3C) , whereas nonexpressing clones (clone nos. 15 and 18 in Fig. 3C ; data not shown) showed 400% to 600% apoptosis, strongly suggesting that caspase-8 activity is necessary for TGFh1-induced cell death. We have not been able to isolate NRP clones expressing FLIP L despite several attempts using constructs driven by a variety of promoters.
Although physiologic levels of FLIP L have been consistently shown to inhibit caspase-8 -dependent apoptosis, the expression of exogenous FLIP L can induce apoptosis (35) (36) (37) (38) (39) , and indeed, this might account for our inability to isolate clones expressing FLIP L . Therefore, to determine if FLIP overexpression can inhibit TGFh apoptosis, we transfected NRP cells with either a HA-tagged FLIP S construct, or the corresponding empty vector and isolated clonal lines. During our initial screen, 48 G418-resistant clones were isolated and screened for FLIP S expression. Two clones expressing very low levels of FLIP S showed a slight reduction in TGFh-induced apoptosis, whereas one clone expressing a high level of FLIP S was essentially refractory to the apoptotic effects of TGFh ( Supplementary Fig. S2 ). Although there was a strong correlation between FLIP S transgene expression, caspase-3 NRP cells were differentiated and left untreated (À) or treated with 5 ng/ mL of TGFh1 (+) for the indicated times (h). Cytoplasmic extracts were separated by SDS-PAGE and the resulting immunoblots probed with an anti-rat FLIP antibody (see Materials and Methods) or anti-actin antibody. Chemiluminescent signals were detected and quantified using a CCCD camera. Inverted images of the chemiluminescence (top ). Columns, mean actin normalized FLIP levels, relative to the untreated control; bars, SE (bottom ). *, P < 0.05, significant reduction versus 0 h control by ANOVA (n = 3). B. FLIP mRNA levels decrease during TGFh1 treatment.
Columns, average message levels at each time (indicated below), adjusted for h-actin levels, then normalized to the untreated control group (0 h) for comparison; bars, SE (n = 5). *, P < 0.05, significant reduction versus paired controls by Student's t test. Two of 48 G418-resistant clones in this second set expressed relatively high levels of FLIP S (Fig. 4B, top) , with clone no. 66 expressing several times more FLIP S than clone no. 48. Extended exposure of the immunoblot reveals that three additional clones displayed low levels of expression (Fig. 4B , second panel). Each of these low expressing clones (in normal growth medium) has similar levels of endogenous FLIP L when normalized to actin (Fig. 4B , third and fourth panels). Additional anti-FLIP immunoblots (data not shown) showed that clone nos. 48 and 66 expressed the exogenously derived FLIP S at levels approximately equivalent to the level of endogenous FLIP L , whereas clone nos. 61, 43, and 53 produced significantly less of the exogenous short isoform relative to the level of the endogenous long isoform. Apoptosis of the differentiated NRP cells in response to TGFh1 treatment (when the endogenous FLIP L is degraded) ranged from 280% to 375% for the vector clones (Fig. 4A , V2 lane; data not shown) and nonexpressing clones (nos. 44 and 51 in Fig. 4A ; data not shown). The three low-expressing clones had an intermediate level of apoptosis (140-180%), whereas the clone with a higher level of FLIP S expression (no. 48) had 130%, and the highest expressor (no. 66) only 80% of the TGFh1-induced apoptosis relative to untreated controls (Fig. 4A) . Again, caspase-3 activity was highly induced (f15-fold) after TGFh1 treatment of the vector-containing and FLIP S -nonexpressing clones (Fig. 4C) . The low-expressing clones displayed attenuated induction (f2-fold), whereas the two high expressors showed no induction of caspase-3 activity ( 
Death Ligand Blockers Do Not Inhibit TGFb1-Induced Apoptosis
TGFh1 both reveals a preexisting cell death signal and induces an additional death signal (Fig. 3A) , and both FLIP and crmA are thought to block DR-induced activation of the apical caspase-8 and caspase-10. Because the extracellular death ligands signal through these receptors via these caspases, we next sought to determine whether death ligand signaling is necessary for TGFh1-induced cell death. Fas DR has been implicated in prostate apoptosis (40-42), so we sought to determine if TGFh1-induced apoptosis requires Fas signaling by employing Fas-Fc to block the FasL-Fas interaction. Initial experiments using human Fas-Fc did not block cell death (data not shown). Because rat Fas differs from human Fas, a chimera (rFas-Fc) containing a CD5 leader, the extracellular domain of rat Fas fused to Fc and a carboxyl-terminal HA tag was expressed in 293T cells and purified on a protein A column (Fig. 5A) . Jurkat cells were then used to validate the molecular reagents (Fig. 5B) . Specifically, treatment with 200 pg/mL of membrane-bound FasL (mFasL) induced cell death after 18 h (Fig. 5B, dark gray columns) . Further addition of Fc had no effect, whereas rFas-Fc completely blocked mFasL-mediated killing (Fig. 5B , dark gray columns, middle Reduced FLIP L triggers cell death of NRP cells and potentiates TGFh1-induced apoptosis. NRP cells were transfected with siRNA targeting luciferase (Luc) or two separate sites on FLIP L alone or in combination. Black columns, adherent cells, relative to the luciferase control, following 72 h of differentiation; bars, SE. Gray columns, adherent cells following 72 h of TGFh1 treatment of differentiated cells; bars, SE (n = 3). Middle, immunoblots probed with an anti-rat FLIP antibody or anti -h-actin antibody. Bottom: columns, mean h-actin normalized FLIP levels relative to the untreated control for the above immunoblots, quantified as described in Fig. 2A . B. FLIP L and crmA protect NRP cells from TGFh1-induced cell death. NRP cells were transiently transfected with the indicated DNA and differentiated, followed by treatment with or without TGFh1. Columns, mean percentage of live cells from TGFh1-treated transfectants relative to untreated transfectants at 72 h; bars, SE. C.
CrmA-expressing NRP cell clones are protected from TGFh1-induced apoptosis. G418-resistant clones (numbered) were shifted to differentiation medium, treated with 5 ng/mL of TGFh1 and apoptotic (floating) cells counted after 72 h (n = 3). Columns, average percentage of apoptosis; bars, SE (see Materials and Methods). Bottom, immunoblot of stable crmA-transfected clones (numbered) probed with an anti-crmA antibody. Positive control (+) is lysate from 293T cells transiently transfected with crmA.
versus right). If TGFh1-induced apoptosis is mediated via the FasL-Fas pathway, the kinetics of death should be similar for mFasL and TGFh1. Indeed, when NRP cells are treated with mFasL, there is very little cell death apparent until 48 h and it is maximal at 72 h ( Fig. 5C ; data not shown). In addition, NRP cells are less sensitive to mFasL compared with Jurkat cells, with a 10-fold higher dose (2 ng/mL) required for maximal NRP killing (data not shown). The addition of rFas-Fc blocks mFasLinduced killing (Fig. 5C , compare black and dark gray columns), but does not affect killing at two doses of TGFh1 (1 ng/mL, white columns; 5 ng/mL, light gray columns). Similarly, neither 5-nor 25-fold increases in the amount of rFasFc significantly reduced the apoptosis induced by 1 ng/mL of TGFh1 in these cells (Fig. 5D) .
Because rFas-Fc was unable to block TGFh1-induced apoptosis, we examined whether TRAIL or TNFa, which also act via FLIP-inhibitable caspase-8 or -10, might be induced by TGFh1 and blocked by FLIP. Specifically, because TRAIL kills neoplastic and normal human prostate epithelial cells (18) via activation of the apical caspases (43), we examined its role in TGFh1-mediated apoptosis. Human TRAIL can bind two death-inducing receptors, DR4 and DR5, as well as three decoy receptors and OPG (44) , but the DR4 receptor does not exist in rodents (45) . Fc fusions of the extracellular domains of these receptors block TRAIL-induced cell death (18) . As in Fig. 5 , we employed Jurkat cells to show the utility of human DR5-Fc in blocking TRAIL signaling. Purified DR5-Fc (250 ng/mL) was able to block TRAIL-induced cell death at doses up to 50 ng/mL (Fig. 6A , gray versus black columns). TRAIL killed NRP cells but, as was the case for mFasL, only at significantly higher concentrations relative to the dose that was effective in killing Jurkat cells (Fig. 6B) . Because DR5-Fc was most effective at blocking lower TRAIL doses, we treated NRP cells with varying doses of TGFh1, from 0.1 ng/mL, which is sublethal, up to 5 ng/mL, and found the minimum concentration necessary to induce f50% apoptosis is f0.5 ng/mL (Fig. 6C, black columns) . DR5-Fc failed to inhibit TGFh1-induced apoptosis of NRP cells, even at the half-maximal dose (0.5 ng/mL) at which the effect of DR5-Fc on any TRAIL signaling should be most evident (Fig. 6C, gray versus black  columns) . The third death ligand capable of inducing death in human prostate cells, TNFa, also caused apoptosis of NRP cells at all doses tested (black columns, Fig. 6D ). Etanercept (Enbrel), a therapeutic blocking reagent for TNFa signaling, is a fusion of the TNFRII extracellular domain and Fc. TNFa does not kill Jurkat cells, therefore, the efficacy of blocking cannot be tested in this system, but etanercept blocks TNFainduced apoptosis of NRP cells at 1 Ag/mL (Fig. 6D , white columns) or 5 Ag/mL (Fig. 6D , gray columns) with no toxicity even at these high doses (Fig. 6D) . Either dose of etanercept failed to inhibit TGFh1-induced cell death, even at a minimally effective dose of TGFh1 (0.125 ng/mL; Fig. 6E ).
Finally, in order to investigate whether there is some cryptic induction of ligand secretion inaccessible to the blocking reagents or whether sensitization to death ligand signals could occur via receptor up-regulation, we investigated whether TGFh1 might induce the mRNA levels of any of the ligands and receptor pairs. We developed quantitative reverse transcription-PCR assays for the rat ligands and receptors and measured mRNA levels for each in differentiated NRP cells and TGFh1-treated cells. FasL and Fas levels were not induced by TGFh1 treatment at any time examined (Fig. 7A , black and gray columns, respectively). TRAIL showed a trend towards induction at 24 and 48 h, and was significantly increased (P < 0.01) after 72 h TGFh1 treatment, relative to the differentiated control cell RNA, whereas DR5 levels remained unchanged (Fig. 7B, black and gray columns, respectively) .
TNFRI levels were not induced by TGFh1 (Fig. 7C , gray columns), but TNFa was elevated within 24 h of treatment (P < 0.05) and showed a trend towards increased levels, relative to the differentiated control at all other times examined (Fig. 7C, black columns) .
Insulin Regulates Survival via FLIP in NRP Cells
Finally, because nondifferentiated cells are resistant to TGFh1-induced apoptosis, we sought to determine if growth factors that modulate the growth and differentiation of NRP cells also regulate FLIP expression. Insulin and epidermal growth factor (EGF) both stimulate NRP proliferation in the presence of 10% fetal bovine serum (31), but only insulin [as well as the related growth factor, insulin-like growth factor (IGF-I)] inhibits the differentiation of NRP cells from the basal to the luminal phenotype (32) . The addition of insulin to the cell medium during differentiation effectively blocks TGFh1-induced apoptosis as reported previously (33, 34) , whereas the addition of EGF does not (Fig. 8A, gray columns) . FLIP knockdown in these insulin-treated differentiated cells restores the TGFh1-induced apoptosis lost in the insulin-treated cells (Fig. 8A, gray columns) . Reduction of FLIP levels using siRNA in differentiated NRP cells grown in the presence of insulin causes f30% cell death, even in the absence of TGFh1, but dramatically less than the f65% cell death seen in the absence of insulin (compare black bar in Fig. 8A with Fig. 3A) . Both insulin and EGF induce an increase in the level of FLIP L but the kinetics are distinct. Specifically, when NRP cells are grown in GM3 differentiation medium plus insulin, FLIP L protein levels increase significantly after 6 h (Fig. 8B,  lanes 3-4) and remain elevated at 24 and 48 h (Fig. 8C, lanes  2 and 6) . In contrast, when EGF is added to differentiating NRP cultures, FLIP L levels increase only slightly after 6 h (Fig. 8B, lanes 1-2) before increasing significantly at 24 and 48 h (Fig. 8D, lanes 2 and 6) . Figure 2 shows that treatment of differentiated NRP cells with TGFh1 downregulates FLIP L protein levels and coordinately induces apoptosis. Similarly, Fig. 8C-D (lanes 3-4 and 7-8) shows that TGFh1 reduces FLIP L expression and induces PARP cleavage, a marker of apoptotic caspase activation. Insulin prevents the TGFh1-induced reduction of FLIP L at both 24 h (Fig. 8C, lane 1 versus lane 3 ) and 48 h (Fig. 8C , lane 5 versus lane 7) and effectively prevents PARP cleavage. EGF is not effective at maintaining FLIP L expression and is only partly effective at inhibiting PARP cleavage (Fig. 8D, lanes 1,  3, 5, and 7) . Thus, treatment of NRP cells with EGF and insulin during differentiation modulates FLIP L levels and further shows that TGFh1-induced apoptosis is inversely correlated with the level of FLIP L expression.
Discussion
Androgen withdrawal -induced cell death seems to be mediated, at least in part, by TGFh that is secreted in response to androgen ablation. Significantly, the NRP cell line apoptoses when treated with TGFh1, as shown by caspase activation, DNA fragmentation, and a decline in cell number (Fig. 1) . Because we previously showed that both FLIP mRNA (2) and protein levels 4 decline following castration in rats, we examined NRP cells and found that both FLIP protein and mRNA decline following TGFh1 treatment (Fig. 2) . Furthermore, NRP cells die when FLIP protein levels are reduced and this is potentiated by concomitant treatment with TGFh1 (Fig. 3) . We therefore sought to determine whether enforced, continuous expression of FLIP would be sufficient to block TGFh1-induced apoptosis of NRP cells. Indeed, transient expression of FLIP L or the apical caspase inhibitor crmA protected against TGFh1-induced cell death. Stable clones expressing crmA completely blocked this death (Fig. 3) , but we were unable to isolate NRP cell lines stably expressing FLIP L . FLIP L overexpression has been reported to induce cell death in some cell lines, so to circumvent this, we chose to express FLIP S . Although we do not necessarily believe that FLIP S is the relevant FLIP isoform in NRP cells (indeed, we have not detected FLIP S in NRP cells; see Fig. 2 and Supplementary  Fig. S1 ), FLIP S does not induce cell death when overexpressed. When NRP cells were stably transfected with an HAtagged, constitutively expressed FLIP S gene, no evidence of TGFh1-induced apoptosis was seen (Supplementary Figs. S2-S3; Fig. 4) . Furthermore, NRP clones expressing very low levels of FLIP S showed no evidence of inhibition of apoptosis, whereas clonal cell lines expressing moderate levels of FLIP S showed an intermediate phenotype, suggesting that the dose of FLIP S expression is crucial in determining its effectiveness in blocking cell death in normal prostate cells. This stoichiometry-dependent effect of FLIP S is consistent with the idea that this protein acts in a dominant inhibitory manner to block the function of caspase-8.
If FLIP S antagonizes TGFh1-induced apoptosis by inhibiting caspase-8, both proximal and distal caspase -mediated cleavage events should be attenuated. As expected, TGFh1 treatment of untransfected NRP cells induced significant cleavage of both caspase-3 and PARP, a caspase-3 substrate and apoptosis marker (data not shown), as well as the caspase-3 peptide substrate (Fig. 1) . However, when we examined caspase activation in TGFh1-treated FLIP S -expressing clones, we found little or no increase in caspase-3 activity. Furthermore, neither caspase-3 itself nor PARP are cleaved in the clones expressing intermediate or high levels of exogenous FLIP S ( Fig. 4;  Supplementary Fig. S3 ). Taken together, these data indicate that FLIP S expressing clones, which are refractory to TGFh1-induced cell death, are not undergoing key biochemical changes that normally accompany apoptosis in NRP cells.
Proximally, we sought to measure caspase-8 activation because caspase-8 is the likely target of the antiapoptotic action of FLIP S . In other TGFh1-sensitive human cells, immunoblotting of treated cells with an antibody directed against human caspase-8 detected a slight increase in the caspase-8 cleavage, whereas enzymatic assays revealed a small increase in caspase-8 activity (46) . Unfortunately, neither this human antibody nor other antibodies tested detect rat caspase-8 active Jurkat cells were pretreated with diluent (black columns ) or 250 ng/mL of DR5-Fc (gray columns ) for 3 h, followed by human TRAIL at the indicated concentrations. After 18 h, WST-1 conversion was measured and plotted as in Fig. 5B (n = 4) . B. NRP cells were killed by mTRAIL. NRP cells were treated with the indicated concentration of mouse TRAIL. After 72 h, WST-1 conversion was measured as in Fig. 5B (n = 4) . C. NRP cell killing by TGFh1 was not blocked by DR5-Fc. NRP cells were pretreated for 3 h with diluent (black columns ) or 250 ng/mL of DR5-Fc (gray columns) and then treated with the indicated concentration of TGFh1. After 72 h, WST-1 conversion was measured as in Fig. 5B (n = 4) . D. NRP cell killing by TNFa was blocked by etanercept. NRP cells were pretreated with diluent (black columns ), 1 Ag/mL (white columns ), or 5 Ag/mL (gray columns ) of etanercept for 3 h, followed by human TNFa at the indicated concentrations. After 72 h, WST-1 conversion was measured and plotted as in Fig. 5B (n = 4) . E. NRP cell killing by TGFh1 was not blocked by etanercept. NRP cells were pretreated for 3 h with diluent (black columns ), 1 Ag/mL (white columns ), or 5 Ag/mL (gray columns ) of etanercept and then treated with the indicated concentration of TGFh1. After 72 h, WST-1 conversion was measured as in Fig. 5B (n = 4) . fragments (data not shown) and we have not been able to identify a suitably sensitive antibody directed against rat caspase-8. Thus, we also assayed for cleavage of caspase peptide substrates. Although we could readily detect an increase in caspase-8 activity at late time points (36-48 h), we could not detect activation of either caspase-8 (or -9) at 6, 12, or 18 h following TGFh1 addition (data not shown). Moreover, the caspase-8 and caspase-9 activities observed at late time points were eliminated when we included an inhibitor of caspase-3, which is highly induced in these lysates (Fig. 1C) and cross-cleaves both the IETD (caspase-8) and LEHD (caspase-9) substrates (data not shown). The relatively low levels of TGFh1-induced caspase-8 activity, which may be a result of the comparatively slow onset of cell death in these prostate epithelial cells versus T cells, prevented us from determining if FLIP S overexpression could indeed inhibit caspase-8 activity.
Because NRP apoptosis is blocked by FLIP S , and FLIP S is thought to inhibit apical caspases bound to DRs, TGFh1 may act by either inducing (or stabilizing) the expression of a death signal and/or by revealing the activity of a preexisting death signal through the reduction of caspase inhibition due to FLIP degradation. Indeed, both of these mechanisms play a role in the TGFh1-induced apoptosis of NRP cells, as reducing FLIP levels by siRNA alone results in apoptosis, and this is potentiated by further treatment with TGFh1 (Fig. 3A) . The death signal induced is likely to be one of the extracellular DR ligands which activate the apical caspases. This can be tested by exploiting the observation that fusions between the extracellular domain of a receptor and the immunoglobulin Fc domain block DR ligand -induced apoptosis. To determine if FasL is involved in TGFh1-induced NRP apoptosis, we measured cell death in the presence of rFas-Fc, which blocks the interaction between FasL and Fas. Although FasL induced apoptosis in NRP cells, rFas-Fc protein failed to block TGFh1-induced NRP cell death (Fig. 5) . Neither Fas ligand nor receptor mRNA levels changed after 72 h (Fig. 7A) , further arguing against a role for this signaling pathway.
TRAIL is thought to be a potent inducer of prostate cell death (20) and TRAIL receptors are expressed in normal prostate epithelial cells (18, 47) as well as a variety of prostate cancer cell lines (48, 49) . Blocking DR5 rescues TRAILinduced apoptosis in normal human prostate epithelial cells (18) . Although TRAIL induced NRP apoptosis, blocking experiments with DR5-Fc fusion protein failed to inhibit TGFh1-induced cell death (Fig. 6C) . Neither TRAIL nor DR5 mRNA levels were significantly regulated by TGFh1 after 48 h, and TRAIL was induced only at 72 h (Fig. 7B ), well after TGFh1 had induced apoptosis in the NRP cells. Although our data argue against a role for TRAIL in TGFh1-mediated NRP apoptosis, it remains possible that the human TRAIL receptorFc fusions we employed failed to block rat TRAIL signaling because of sequence differences between the human and rat TRAIL receptors. Consistent with this possibility, others have reported that human DR4-Fc inhibits TGFh1-induced apoptosis of human hepatoma cell lines (50) .
TNFa can induce cell death as well as cell survival, dependent in part on the nature of the receptor complexes formed in response to ligand binding (51) . An extended duration TNFa signal induces the degredation of FLIP, sensitizing the cell to the apoptotic effect (52) . In most prostate epithelial cells, including normal epithelial cells and the PC-3 and DU145 cell lines, nuclear factor nB is activated by TNFa and they do not apoptose (53) . The LNCaP cell line undergoes apoptosis in response to TNFa, but is defective in the regulation of nuclear factor nB and therefore may be a poor model for normal prostate epithelium (53, 54) . In contrast, the differentiated NRP cells are sensitive to TNFa induction of apoptosis, and this can be completely blocked using etanercept (Fig. 6D) . TNF receptor mRNA levels were unchanged at all times examined, but the mRNA level of TNFa shows a trend to increase rapidly after TGFh1 addition, and is significantly increased after 24 h (Fig. 7C) . Although etanercept is derived from the human protein, it is nonetheless effective at blocking rodent TNFa function in vivo (55) . Despite the induction of TNFa mRNA in the NRP cells following TGFh1 treatment, the induction of apoptosis is not blocked by etanercept (TNFR-Fc), and so, it is unlikely that TGF induces the secretion of soluble or otherwise accessible TNFa, which goes on to induce the apoptosis of adjacent NRP cells. It is possible that the TGFhinduced TNFa is acting on a receptor that is inaccessible to the etanercept, such as intracellularly, or on a receptor on the same cell membrane while it is being secreted, although such mechanisms are strictly hypothetical.
Other than TNFa, TGFh1 did not induce the mRNA levels of the major cell death ligands or receptors in a physiologically relevant time pattern. Because DNA fragmentation is apparent by 24 h post-TGFh1, any death signal must precede 24 h. Although the other DR ligands (TWEAK, LIGHT, RANKL, etc.) are also potential candidates to mediate TGFh1-regulated cell death (56), we believe that this is unlikely. TWEAK and other ligands are relatively inefficient inducers of apoptosis (56, 57) and there are no reports of their activity in prostate epithelial cells. It is also formally possible that TGFh1 induces multiple extracellular death ligands in NRP cells and blocking any one is not sufficient to inhibit cell death. However, there is precedence for the possibility that FLIP blocks TGFh1-induced apoptosis in a cell DRindependent manner. Specifically, TGFh1 treatment of SNU-620 gastric carcinoma cells activates caspase-8 and induces caspase-8 -dependent apoptosis, but this effect is not blocked by Fas-Fc nor is it enhanced by FasL (58). Because TGFh1-induced cell death in SNU-620 cells requires functional FADD, FLIP would be expected to act in a dominant inhibitory manner in this cell line. Thus, a similar mechanism could be operative in NRP cells.
Finally, to better understand how the process of NRP differentiation sensitizes cells to TGFh1-induced apoptosis, we investigated the modulation of FLIP expression by mitogens. Insulin and IGF-I protect against TGFh1-induced apoptosis, whereas EGF does not ( Fig. 8; ref. 34 ). IGF-I and insulin, which signal via similar pathways, act in two ways: inhibiting the activation of Smad3, and maintaining the intracellular level of FLIP, even in the presence of TGFh1 (Fig. 8) . Both insulin and IGF-I induce Akt phosphorylation, inhibiting the activity of Smad3 (59) and Bad (60) , and upregulating FLIP (Fig. 8) . Phosphorylated Akt, but not EGFstimulated phosphorylated extracellular signal -regulated kinase, is associated with an increased proliferative index in prostate tumors (61) . Indeed, IGF-I is capable of activating nuclear factor nB (via phosphoinositide-3-kinase and AKT) and thereby increasing the levels of FLIP message and protein in thyroid cancer cells (62) , and has been directly implicated in prostate cancer progression (63) . This suggests that the resistance of insulin-stimulated NRP cells to apoptosis, perhaps acting via sustained expression of FLIP, is reflective of changes in human tumors.
Materials and Methods
Reagents and Antibodies
Caspase substrates (Biomol), mFasL (UBI), ''super killer'' mouse TRAIL, DR5-Fc (Alexis Biochemicals), etanercept (Enbrel, Immunex), human TGFh1 (R&D Systems), human TNFa (Peprotech), anti-HA (Y-11; Santa Cruz Biotechnology) anti-actin (AC-10; Sigma), and anti-PARP (C2.10; Enzyme Systems) were purchased from the indicated suppliers. An antibody (G878) was prepared by immunizing rabbits against the rat FLIP amino-terminal peptide QVEESLDEDEKEC ( Supplementary Fig. S1A ) and then purified by peptide affinity chromatography (data not shown). This antibody reacts with both the long and short forms of rat FLIP when expressed in 293T cells and FLIP L from a variety of rat tissues, whereas FLIP S is detected only in the rat heart ( Supplementary Fig.  S1B ). The antibody detects FLIP in human and rat prostate cells (Supplementary Fig. S1C ).
Cell Culture, Apoptosis Assays, and Transfection
Passage 27 NRP cells were maintained as described (31). Briefly, the cells were cultured in GM2 [DMEM/F12 medium containing 5% fetal bovine serum, 20 ng/mL EGF (BD Biosciences), 0.1 mmol/L dexamethasone (Sigma), 10 ng/mL cholera toxin (Sigma), and 350 nmol/L insulin (Biosource)] and passaged before reaching confluence. NRP cells were discarded after 15 passages, except the FLIP-expressing clones, which range from 20 to 25 passages after selection. Apoptosis assays were done in differentiation media (GM3; DMEM/F12 containing 1% calf serum, 15 mmol/L HEPES, and 0.1 mmol/L dexamethasone) using 5 ng/mL of TGFh1 or vehicle (4 mmol/L HCl, 1 mg/mL bovine serum albumin).
After TGFh1 treatment, NRP cells that adhere to tissue culture plates after two PBS washes exclude trypan blue, possess nuclei that appear nonapoptotic following 4 ¶,6-diamidino-2-phenylindole staining, and show no caspase activation by immunoblotting analysis. In contrast, the detached cells were uniformly apoptotic after being recovered from the GM3 medium and PBS washes. These detachable (floating) cells are apoptotic by DNA laddering, caspase activation by immunoblot analysis, and 4 ¶,6-diamidino-2-phenylindole nuclear staining (64) . Quantification of NRP detachable cells and adherent cells released by trypsin treatment after the PBS washes using a Coulter counter was therefore used as a measure of TGFh1-induced apoptosis of NRP cells. The percentage of adherent cells (% live cells) represents the ratio of live, adherent cells in the TGFh1-treated dishes relative to the untreated, differentiated control dishes at 72 h. The percentage of apoptotic cells (% apoptosis) similarly represents the ratio of detachable cells.
TGFh1 treatment of differentiated NRP cells induces a 3-fold to 4-fold increase in the number of floating cells after 72 h, and hence, 300% to 400% apoptosis (for example, columns labeled P in Figs. S2a and S3a).
Both the rat FLIP S and FLIP L cDNAs were cloned by reverse transcription-PCR into pBluescript, transferred to a vector containing a carboxyl-terminal HA tag and then into the KpnI and ApaI sites of pcDNA3.1 (Invitrogen) to create p-ratFLIP S HA and p-ratFLIP L HA. pCrmA was a gift from C. Walsh (University of California-Irvine, Irvine, CA) and includes a neomycin resistance gene and crmA driven by the h-actin promoter. These plasmid were transfected with LipofectAMINE Plus (Life Technologies, Inc.) and assessed directly, or using clones of transfectants selected using G418 (Life Technologies) at 200 ng/mL in GM2.
Immunoblotting
NRP cells were lysed in NP40 buffer [1% NP40, 1 mmol/L NaVO 4 , 100 mmol/L NaF, 2.5 Amol/L of ZnCl 2 , 10% glycerol, 0.2 mmol/L phenylmethylsulfonylfluoride and protease inhibitor cocktail (Sigma) in TBS solution]. The nuclear fraction was removed and resuspended in 6 mol/L of urea for PARP determination. Either lysate was electrophoresed on SDSpolyacrylamide gels, immunoblotted to nitrocellulose, blocked in 5% nonfat dry milk dissolved in TBS plus 0.1% Tween, and probed overnight at room temperature with antibodies. Filters were washed, incubated with goat anti-rabbit horseradish Columns, average message levels at each time (indicated below), adjusted for h-actin levels, then normalized to the untreated control group (0 h) for comparison; bars, SE (n = 3). *, P < 0.05; **, P < 0.01, significant reduction versus 0 h. A. FasL mRNA (black columns ) and Fas mRNA (gray columns ). B. TRAIL mRNA (black columns ) and DR5 mRNA (gray columns ). C. TNFa mRNA (black columns ) and TNFRI mRNA (gray columns ). peroxidase -linked secondary antibody (Pierce) for 2 to 4 h at room temperature, washed and finally incubated with chemiluminescence reagent (Super Signal West Pico; Pierce) and then exposed to film or a cooled charged-coupled digital camera (Kodak 4000R).
DNA Isolation and Labeling
Attached and floating NRP cells were pooled and DNA was extracted by lysing cells in 7 mol/L of guanidine hydrochloride followed by further purification using the Wizard system (Promega) as described previously (2) . DNA fragments were end-labeled with 32 P-ddATP and terminal deoxynucleotide transferase as previously described (65) . The labeled DNA was fractionated on a 2% agarose gel and the gel was dried and autoradiographed.
siRNA-Mediated Knockdown of FLIP
For siRNA-mediated FLIP knockdown, cells were plated in GM2 without antibiotics. The cells were transfected 4 h later with 20 nmol/L of control (Luciferase, 5 ¶-UAAGGC-UAUGAAGAGAUAC-3 ¶) or FLIP-specific (DED2; FLIP no. 1, 5 ¶-GAAUAGACUUGAAGACAAAUU-3 ¶; FLIP no. 2, 5 ¶-GUUCCGAUCAGUUGAAUUUUU-3 ¶) oligomers (or 10 nmol/L each when combined) using 3.5 AL/mL of Dharma FECT 4 transfection reagent. After 24 h, transfected cells were split into two dishes and differentiated in GM3 media for three h, and then treated with or without 5 ng/mL of TGFh1 for 72 h. Transfection reagent and siRNAs were purchased from Dharmacon.
Caspase Activity Assays
NRP cells were treated with TGFh1 or vehicle for 36 h. Adherent and floating cells were pooled, harvested, washed with PBS, and counted. The cells were lysed in 20 mmol/L of EDTA, 5 mmol/L of Tris (pH 8.0), and 0.5% Triton X-100 to isolate caspase-containing cytoplasm. Extracts from 400,000 cells were diluted into 0.1% CHAPS, 50 mmol/L of DTT, 50 mmol/L of HEPES (pH 7.4), 100 mmol/L of NaCl, 1 mmol/L of EDTA, and 10% glycerol, 50 Amol/L of DEVD-pNA (caspase-3 substrate), 100 nmol/L of IETD-CHO (caspase-8 inhibitor), 5 nmol/L of YVAD-CHO (caspase-1 inhibitor), and incubated at 37jC. Production of pNA was monitored at 405 nm for 3 h and activity was determined from the slope of the curve in the linear range for each sample. Each sample was assayed in triplicate. 
